Nautilus Biotechnology, Inc. Q3 2026 Earnings Recap

Nautilus shares rose 18.4% after earnings. The call’s positive signal was the company’s sharpened focus on proteoforms, with management saying its development roadmap is underway and pointing to demand from the scientific community.

Key Takeaways

• Nautilus has concentrated resources on proteoforms and says it effectively tripled the people and resources focused on proteoform development.
• The company aims to develop 20 proteoform assays by the middle of 2028.
• Management described its Voyager platform and Iterative Mapping method as designed to read intact protein molecules at scale and resolve their functional states.
• Nautilus cited demand for more proteoforms, sample types, and applications, along with its participation in the SEEDS Consortium, funded up to $51.7 million by ARPA-H.
• The supplied transcript excerpt does not include quarterly financial figures or a detailed financial outlook, limiting assessment of the earnings and near-term business performance.